Literature DB >> 25059638

Management of chronic Giardia infection.

Angel A Escobedo1, Kurt Hanevik, Pedro Almirall, Sérgio Cimerman, Maydel Alfonso.   

Abstract

Advances in our understanding of chronic giardiasis (CG) may improve our care of patients in this stage of the disease. This review proposes a new concept of CG and highlights the recent advances in our understanding and management of this condition. According to this review, management requires, initially, an accurate diagnosis, which may exclude several conditions that can mimic CG. Optimal treatment requires a tailored approach which includes the recognition of the known modifiable causes of this health condition, assessment of symptoms and potential complications, their treatment utilizing, if necessary, a multidisciplinary team, and an ongoing monitoring for the effect of therapy - weighing the efficacy of individual drugs - all of these together may lead to a successful treatment of CG.

Entities:  

Keywords:  5-nitroimidazoles; Giardia; albendazole; chronic giardiasis; nitazoxanide; quinacrine; resistance; tinidazole; treatment failure

Mesh:

Substances:

Year:  2014        PMID: 25059638     DOI: 10.1586/14787210.2014.942283

Source DB:  PubMed          Journal:  Expert Rev Anti Infect Ther        ISSN: 1478-7210            Impact factor:   5.091


  10 in total

1.  Human Memory CD4+ T Cell Immune Responses against Giardia lamblia.

Authors:  Christina Skår Saghaug; Steinar Sørnes; Dimitra Peirasmaki; Staffan Svärd; Nina Langeland; Kurt Hanevik
Journal:  Clin Vaccine Immunol       Date:  2015-09-16

2.  Giardia co-infection promotes the secretion of antimicrobial peptides beta-defensin 2 and trefoil factor 3 and attenuates attaching and effacing bacteria-induced intestinal disease.

Authors:  Anna Manko; Jean-Paul Motta; James A Cotton; Troy Feener; Ayodele Oyeyemi; Bruce A Vallance; John L Wallace; Andre G Buret
Journal:  PLoS One       Date:  2017-06-16       Impact factor: 3.240

Review 3.  Treatment-refractory giardiasis: challenges and solutions.

Authors:  Marco Lalle; Kurt Hanevik
Journal:  Infect Drug Resist       Date:  2018-10-24       Impact factor: 4.003

4.  Dientamoeba fragilis - the most common intestinal protozoan in the Helsinki Metropolitan Area, Finland, 2007 to 2017.

Authors:  Jukka-Pekka Pietilä; Taru Meri; Heli Siikamäki; Elisabet Tyyni; Anne-Marie Kerttula; Laura Pakarinen; T Sakari Jokiranta; Anu Kantele
Journal:  Euro Surveill       Date:  2019-07

5.  Associations between enteric pathogen carriage and height-for-age, weight-for-age and weight-for-height in children under 5 years old in urban Dhaka, Bangladesh.

Authors:  David Berendes; Drew Capone; Jackie Knee; David Holcomb; Sonia Sultana; Amy J Pickering; Joe Brown
Journal:  Epidemiol Infect       Date:  2020-02-27       Impact factor: 2.451

Review 6.  Repurposing Chloroquine Against Multiple Diseases With Special Attention to SARS-CoV-2 and Associated Toxicity.

Authors:  Siya Kamat; Madhuree Kumari
Journal:  Front Pharmacol       Date:  2021-04-12       Impact factor: 5.810

7.  First report of Giardia duodenalis and Enterocytozoon bieneusi in forest musk deer (Moschus berezovskii) in China.

Authors:  Yuan Song; Wei Li; Haifeng Liu; Zhijun Zhong; Yan Luo; Yao Wei; Wenlong Fu; Zhihua Ren; Ziyao Zhou; Lei Deng; Jianguo Cheng; Guangneng Peng
Journal:  Parasit Vectors       Date:  2018-03-26       Impact factor: 3.876

8.  Repositioning Quinacrine Toward Treatment of Ovarian Cancer by Rational Combination With TRAIL.

Authors:  Rui Liang; Yuanfei Yao; Guangyu Wang; Er Yue; Guangchao Yang; Xiuying Qi; Yang Wang; Ling Zhao; Tongsen Zheng; Yanqiao Zhang; Edward Wenge Wang
Journal:  Front Oncol       Date:  2020-07-16       Impact factor: 6.244

9.  Recirculation of Giardia lamblia Assemblage A After Metronidazole Treatment in an Area With Assemblages A, B, and E Sympatric Circulation.

Authors:  Maria Fantinatti; Luiz Antonio Pimentel Lopes-Oliveira; Tiara Cascais-Figueredo; Phelipe Austriaco-Teixeira; Erika Verissimo; Alexandre Ribeiro Bello; Alda Maria Da-Cruz
Journal:  Front Microbiol       Date:  2020-10-22       Impact factor: 5.640

10.  Albendazole and Mebendazole as Anti-Parasitic and Anti-Cancer Agents: an Update.

Authors:  Jong-Yil Chai; Bong-Kwang Jung; Sung-Jong Hong
Journal:  Korean J Parasitol       Date:  2021-06-21       Impact factor: 1.341

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.